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Resumo 
A metanfetamina (METH) é uma droga psicostimulante, altamente aditiva e uma das 
mais utilizadas em todo o mundo. A dependência de drogas é considerada uma doença 
cerebral crónica, onde as recaídas são frequentes, associada a doenças sistémicas graves, 
o que levanta preocupações socioeconómicas e de saúde pública relevantes. Embora 
indivíduos dependentes geralmente apresentem condições fisiopatológicas graves, o 
tratamento da toxicodependência é atualmente escasso e os mecanismos pelos quais a 
dependência se desenvolve não são ainda completamente conhecidos. Assim, é essencial 
explorar estes mecanismos, a fim de encontrar possíveis alvos terapêuticos. A METH, em 
particular, conduz a uma disfunção de longo prazo de neurónios dopaminérgicos e 
glutamatérgicos, comprometimento de células da glia e stress oxidativo elevado. A 
exposição a psicostimulantes também afeta a morfologia neuronal, o aumento do 
comprimento de neurites e a densidade de espículas dendríticas em várias regiões do 
cérebro. 
Para explorar esta questão, realizamos uma análise de RNA-Seq em frações de 
soma e de neurites de neurónios do hipocampo em cultura, o que revelou padrões de 
expressão diferenciados em vários genes em neurónios expostos a METH. Inicialmente, 
selecionamos genes expressos diferencialmente no soma, relacionados com o metabolismo, 
a sinalização celular, o ciclo celular ou transcrição/tradução. Foram selecionados 5 genes 
que poderiam estar relacionados com a neuroinflamação e interação neurónio/glia: 
Optineurin (Optn), Olfactomedin 4 (Olfm4), RAS guanyl releasing protein 1 (Rasgrp1), RelB 
Proto-Oncogene (RelB) e Early B-cell factor 3 (Ebf3). 
Realizou-se RT-qPCR para validar a expressão dos candidatos selecionados, e 
confirmou-se que a exposição a METH aumenta significativamente os níveis de expressão 
de mRNA de Olfm4 em culturas primárias de neurónios do hipocampo. A expressão proteica 
foi avaliada através de western blot e imunocitoquímica, revelando que os níveis de proteína 
Olfm4 estão diminuídos. Esta é uma proteína da matriz celular conhecida por interagir com 
integrinas e metaloproteínases para além de poder estar envolvida na regulação da 
neuroinflamação, como tal é alvo de interesse no contexto da exposição a drogas 
psicoestimulantes. 
Analisámos assim a influência da METH na expressão de fatores inflamatórios 
através de RT-qPCR, embora sem sucesso. Além disso, avaliamos o efeito da METH e da 
proteína Olfm4 em proteínas relacionadas com a matriz extracelular (Cldn5, ZO-1, MMP2, 
Src e RhoA) através de análises de western blot, imunocitoquímica, zimograma e FRET. 
Mostramos que a METH não afeta a expressão da Cldn5 e ZO-1. A exposição a METH não 
parece afetar significativamente a atividade da MMP2, levando no entanto a um aumento na 
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ativação da Src, e diminuição da ativação da RhoA. A ativação da Src parece estar também 
associada à expressão da Olfm4. 
 No geral, não observamos efeitos da METH na expressão de proteínas relacionadas 
com a matriz extracelular em neurónios em cultura, nem evidência de contribuição para 
processos de neuroinflamação. No entanto, identificámos o envolvimento da METH na 
ativação da Src, o que associado à consequente inativação da RhoA, pode contribuir para 
as alterações morfológicas neuronais induzidas pela METH. 
 
Palavras-chave: Fatores Inflamatórios; Metanfetamina; Neurónios do Hipocampo; 
Remodelação da Matriz 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FCUP 
Exploring new possible targets in Methamphetamine exposure 
ix 
 
Abstract 
Methamphetamine (METH) is a highly addictive psychostimulant drug and one of the 
most abused worldwide. Drug addiction is considered a chronic and relapsing brain disease 
associated to severe systemic disorders, which raises relevant socio-economic and public 
health concerns. Although addicted individuals usually present severe pathophysiological 
conditions, addiction treatment is currently scant and the mechanisms by which addiction 
develops are still elusive. Therefore it is essential to explore these processes in order to find 
new possible therapeutic targets. METH in particular, leads to long-term dysfunction of 
dopaminergic and glutamatergic neurons, glial impairment and high oxidative stress. 
Interestingly, exposure to psychostimulants also affects neuronal morphology, increasing 
neurite length and dendritic spine density in several brain regions.  
To explore this issue, we conducted an RNAseq analysis from both soma and neurite 
fraction of cultured hippocampal neurons, which revealed differential expression patterns in 
numerous genes in METH exposed neurons. In a first step, we have selected genes 
differentially expressed in the soma, related to metabolism, cell signaling, cell cycle or 
transcription/transduction. We selected 5 genes that were likely to be related to 
neuroinflammation and neuron/glia interplay: Optineurin (Optn), Olfactomedin 4 (Olfm4), 
RAS guanyl releasing protein 1 (Rasgrp1), RelB Proto-Oncogene (RelB) and Early B-cell 
factor 3 (Ebf3). 
We conducted RT-qPCR to validate the expression of the selected candidates, and 
confirmed that upon exposure to METH the Olfm4 mRNA expression levels were significantly 
increased in primary cultures of hippocampal neurons. Protein expression was evaluated 
through western blot and immunocytochemistry, revealing that Olfm4 protein levels are 
decreased. Olfm4 is known to interact with integrins and metalloproteinases and has been 
linked to inflammatory processes.  
We have also analysed METH influence in inflammatory factors expression through 
RT-qPCR, but found no evidence of increased expression of neuroinflammatory factors. 
Moreover, we have assessed METH effect on extracellular matrix related proteins (Cldn5, 
ZO-1, MMP2, Src and RhoA) by western blot, immunocytochemistry, zymography and FRET 
assays. We show that METH does not affect Cldn5 or ZO-1 expression. Also, METH 
exposure does not appear to significantly affect MMP2 activity in neuronal cells, leading 
however to an increase in Src activation, while decreasing RhoA activation. Interestingly, Src 
activation appears to decrease when Olfm4 is knocked down.  
 Overall, we did not observe an effect of METH in the expression of extracellular 
matrix related proteins in neuronal cells, nor evidence of its contribution for the 
neuroinflammatory process described for METH in humans and in vivo models. However, we 
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might have uncovered a new pathway, involving Src activation and consequent RhoA 
inactivation, which may contribute to the METH-induced neuronal morphological alterations.  
 
Keywords: Hippocampal neurons; Inflammatory Factors; Matrix Remodeling; 
Methamphetamine 
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Chapter 1: Introduction 
1.1. Drug addiction 
Drug addiction is a neurobiological, chronical disorder with a persistent possibility of 
relapse. This disorder is characterized by compulsion to seek and take drugs, loss of control 
in limiting intake and development of a negative emotional state when the access to drug is 
prevented. The repetitive drug abuse impairs the normal circuitry of rewarding leading to 
drug-induced neuroplastic changes (Arias-Carrión et al, 2010; Koob and Le Moal, 2005). 
Addicted individuals tend to ignore the negative consequences of drug intake and 
become focused on obtaining and taking drugs (Hyman et al, 2006). The occasional use of a 
drug (with the potential for abuse or dependence) is distinct from heightened drug use and 
the development of a chronic drug-dependent state (Koob, 2006). In fact, only a small 
percentage of individuals exposed to drugs will become addicted, that is, go from controlled 
drug use to compulsive use, despite the adverse consequences. Genetic (50% risk), 
developmental (higher risk in adolescence) and environmental factors (e.g., drug access, 
stress), as well as the type of drug used, are among the causes the rule the propensity of an 
individual to become an addict (Volkow and Li, 2005).  
During the transition from recreational use to addiction, a motivational shift takes 
place. A drug is no longer taken to obtain pleasure from it, but, instead it is taken to satiate 
the intense craving and to relieve the distress of not having access to it (Volkow and Li, 
2004). 
Drug addiction yields a cycle composed of three stages: binge/intoxication, 
withdrawal/negative affect and preoccupation/anticipation (craving). Impulsivity often 
dominates at the early stages, and impulsivity combined with compulsivity dominates at the 
later stages (Koob and Volkow, 2010). 
 
1.2. Methamphetamine 
Methamphetamine (METH), also known by its “street names” as ice, crank, speed or 
crystal (among others), is a synthetically derived psychostimulant drug that acts on the 
central nervous system (CNS) (figure 1). It presents significant abuse potential and 
neurotoxic effects. Due to its small size and lipophilicity, METH can easily cross the blood-
brain barrier (BBB) and acts mostly by causing the release of central and peripheral 
monoamines. It can be synthesized in a straightforward one-step process by reduction of 
ephedrine or pseudoephedrine, or by condensation of phenylacetone and methylamine. 
Being a simple reaction, it only requires rudimentary laboratory equipment to produce (Barr 
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et al, 2006; Cho, 1990; Gold et al, 2009; Nordahl et al, 2003; Panenka et al, 2013; Turowski 
and Kenny, 2015).  
The inexpensive production of METH, together with the low cost and long lasting 
effect of the drug are the main aspects that make METH consumption appealing (reviewed in 
Krasnova and Cadet, 2009). In spite of its addictive properties, oral METH continues to be 
used in the USA as a treatment for various medical conditions, including attention deficit 
hyperactivity disorder (ADHD) and refractory obesity (Kish, 2008). 
METH is typically ingested, smoked, snorted or injected intravenously (Nordahl et al, 
2003). The drug metabolism occurs mostly in the liver, leading to the production of numerous 
metabolites (Caldwell et al, 1972).  
 
 
 
 
 
 
 
 
 
1.3. Historical perspective 
METH was first synthetized in 1893 by Nagayoshi Nagai, a Japanese pharmacologist. 
However, METH use only became widespread during World War II, when USA, Germany 
and Japan made it available to their soldiers in order to enhance their performance. When 
the war ended, surplus army stocks invaded the market and the civilian use increased 
(Anglin et al, 2000; Weisheit and White, 2009). From the 1930s onwards, amphetamines 
were prescribed for a range of medical conditions, including weight loss, treatment of fatigue, 
depression and narcolepsy (EMCDDA, 2014). 
In 1971, the United Nations Convention on Psychotropic Substances declared 
amphetamines and METH schedule II drugs (Final Act of the United Nations Conference for 
the Adoption of a Protocol on Psychotropic Substances, 1971). According to Drug 
Enforcement Administration (DEA), schedule II drugs are substances, or chemicals, with a 
high potential for abuse, which use probably leads to severe psychological or physical 
dependence. Since then, amphetamines manufacturing and sale became forbidden in most 
European countries (EMCDDA, 2014). 
A B 
Figure1. Methamphetamine. Chemical diagram (A) (adapted from Nordahl et al, 2003) and 
tridimensional METH conformation (B) (adapted from PubChem). 
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Figure 2. Amphetamines seizures and usage. Global seizures of amphetamine-type stimulants from 2003 to 2012 
(A) and use of amphetamines in Europe (B) (adapted from World Drug Report 2014 and EMCDDA, 2010). 
Nowadays, amphetamine production is mostly concentrated in North America and 
Asia-Pacific regions. Accordingly, from a total of 144 tons of amphetamine-type stimulants 
seized globally in 2012, half were seized in North America and a quarter in East and South-
East Asia (World Drug Report, 2014). Since mid-2000s, METH production has spread to 
places like South Africa or Iran. Production in new world regions may influence drug markets 
in Europe, in response to new buyers (European Drug Report 2014: Trends and 
developments, 2014).  
The number of amphetamine type stimulants-manufacturing laboratories dismantled 
increased from 12571 in 2011 to 14322 in 2012, being 96% of those manufacturers of METH 
(World Drug Report, 2014; figure 2).  
METH and amphetamine use has been reported in Europe, representing a major 
problem in some specific countries like Czech Republic and Slovakia (Problem amphetamine 
and methamphetamine use in Europe, 2010; figure 2).  
 
 
 
         
     
 
 
 
         
 
 
 
 
 
 
 
 
 
 
A 
B 
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1.4. Clinical effects 
Clinically, METH induces physiological changes similar to those produced by the 
fight-or-flight response. These include the increase of blood pressure, body temperature, 
heart and breathing rate (Anglin et al, 2000). Feelings of euphoria, increased productivity, 
hypersexuality and energy have also been described (Homer et al, 2008; Meredith et al, 
2005). Other effects include acute toxicity, altered behavioral and cognitive functions, as well 
as impaired judgment, euphoric disinhibition, memory loss and neurological damage. Users 
might also experience agitation, aggressiveness, tachycardia, hypertension and 
hyperthermia (Albertson et al, 1999; Barr et al, 2006; Meredith et al, 2005; Lynch and House, 
1992; Murray, 1998; Scott et al, 2007; Thompson et al, 2004; reviewed in Krasnova and 
Cadet, 2009).  
All of these effects may last for several hours, since METH’s half-life varies between 
10 to 12 hours (Schepers et al, 2003). 
Larger doses of METH consumption can lead to life-threatening hyperthermia (above 
41°C), renal and liver failure, cardiac arrhythmias, heart attacks, cerebrovascular 
hemorrhages, strokes and seizures (Albertson et al, 1999; Darke et al, 2008; Perez et al, 
1999). On the other hand, withdrawal can lead to anhedonia, irritability, fatigue, impaired 
social functioning and intense craving for the drug (Brecht et al, 2004; Darke et al, 2008; 
Homer et al, 2008; Sekine et al, 2006; Zweben et al, 2004). 
At the molecular level, METH causes neurodegenerative changes like persistent 
decreases in the levels of dopamine transporters (DAT) in the orbitofrontal cortex, 
dorsolateral prefrontal cortex and the caudate–putamen (McCann et al, 1998; McCann et al, 
2008; Sekine et al, 2003; Volkow et al, 2001a,c; reviewed in Krasnova and Cadet, 2009). It is 
also possible to verify a decline of serotonin transporters (5-HTT) in the midbrain, caudate, 
putamen, hypothalamus, thalamus, the orbitofrontal, temporal and cingulate cortices (Sekine 
et al, 2006). Abnormal glucose metabolism may be present in cortical and subcortical brain 
areas (Volkow et al, 2001b; Wang et al, 2004).  
Noticeable microglial activation is present in the midbrain, striatum, thalamus, 
orbitofrontal and insular cortices of METH abusers. These activated microglia release pro-
inflammatory cytokines, which can both stimulate glutamate (GLU) release and inhibit its 
uptake. This contributes to an increased activity of nitric oxide synthase (NOS) and reactive 
nitrogen species (RNS) production, and also reactive oxygen species (ROS). The activated 
microglia acts as the immune cells of the brain and contributes to the neuroinflammation 
induced by METH (discussed in more detail later in this chapter) (reviewed in Marshall and 
O’Dell, 2012; Sekine et al, 2008).  
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1.5. Methamphetamine action mechanism 
METH action on the CNS is related to its role as a monoaminergic agonist, affecting 
simultaneously the dopamine, noradrenaline and the serotonin transport (reviewed in 
Cruickshank and Dyer, 2009). Under physiological circumstances, monoamines are stored in 
synaptic vesicles by the action of vesicular monoamine transporter-2 (VMAT-2) and released 
into the synaptic cleft upon neuronal activation. They are then transported back into the 
nerve terminal by membrane transporters (DAT, noradrenaline transporter (NET), the 
serotonin transporter (SERT)) and recycled back into synaptic vesicles. METH reverts the 
functioning of DAT, NET, SERT and VMAT, becoming a substitute for dopamine, 
noradrenaline and serotonin (Sulzer et al, 2005), therefore interfering with monoaminergic 
signaling (Fleckenstein and Hanson, 2003; Masson et al, 1999; Pacholczyk et al, 1991).  
This leads to dysfunction in these circuitries, which increases with high-doses and repeated 
administration resulting in persistent monoaminergic deficits (particularly, dopamine deficits) 
(reviewed in Riddle et al, 2006).  
METH reversion of the membrane transporters function, not only allows METH to 
enter the pre-sypnatic terminal, but also results in increased release of monoamines from the 
cytosol to the synaptic cleft while also decreasing monoamine metabolism by inhibiting  
monoamine oxidase (MAO), promoting increased stimulation of postsynaptic monoamine 
receptors (Sulzer et al, 2005).  
METH also generates an increase in the GLU release. The increased extracellular 
GLU activates NMDAR (N-methyl-D-aspartate receptor), which results in a higher 
intracellular Ca2+ influx. This increased intracellular Ca2+ activates enzymatic pathways that 
will cause a rise in the production of ROS and RNS (reviewed in Marshall and O’Dell, 2012; 
reviewed in Riddle et al, 2006).  
METH consumption leads to an unbalance in the mechanisms required for normal 
brain functioning, mainly due to DAergic deficit. METH’s lipophilicity may contribute for it to 
diffuse through cell and organelles membranes, contributing to inhibition of normal 
mitochondrial functioning. This results in decreased energy and increased reactive species 
production. The electron transport chain (ETC) does not work properly, resulting in an 
insufficient ATP production and a higher leakage of high energy electrons, which contributes 
to ROS production. The immense production of ROS and RNS has a prejudicial effect on 
neurons, causing their degeneration (reviewed in Marshall and O’Dell, 2012). 
Figure 3 represents METH induced effects at the synapse, affecting neurons, glia and 
endothelial cells.  
6 FCUP 
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1.6. Methamphetamine and the reward system 
The brain’s main function is to assure individual survival and gene propagation. In 
order to survive, individuals need to acquire substances for their bodily functions (namely 
foods and liquids) as well as adopting certain crucial behaviors (e.g., sexual behavior for 
reproduction or hiding from predators for survival), which require effort to obtain or perform 
(Schultz, 2010; Schultz, 2013).  These substances and/or behaviors are called rewards and 
support learning, decision making and positive emotions like pleasure, desire and happiness 
(Schultz, 2013).  
Rewards can be roughly divided into three components: liking, wanting and learning. 
Liking represents the actual pleasure impact of a reward; wanting links to the motivation for 
the reward, and learning is related with associations, representations and predictions about 
Figure 3. Mechanisms of methamphetamine neurotoxicity. METH enters dopaminergic terminals (1), causing efflux of DA. 
DA metabolism produces reactive species (2) that are transported to extracellular spaces (3) where they are oxidized producing 
ROS. High intracellular concentrations of DA and METH can inhibit ETC in mitochondria (4), causing leakage of high-energy 
electrons resulting in formation of superoxide. METH-induced increases in GLU release (5) stimulate NMDAR on dopaminergic 
terminals leading to increases in intracellular Ca
2+
 that stimulates NOS activity, increasing the production of nitric oxide (NO) 
that may combine with superoxide to form peroxynitrite (
.
ONOO
–
) (6). High intracellular Ca
2+
 can also induce proteolytic 
enzymes (e.g.calpain) (7) that break down structural proteins (e.g.spectrin) resulting in impaired terminal integrity. Furthermore, 
microglia releases ROS and cytokines (8), which contributes to increase extracellular GLU levels. METH causes BBB 
impairment, allowing plasma proteins to enter the brain (9), followed by water and ions, causing brain edema and additional 
physiological disruption of neurotransmission (adapted from Marshall and O’Dell, 2012). 
Cytokines 
Astrocyte 
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future rewards based on past experiences. Rewards can lead to either a conscious or to an 
unconscious response (Berridge and Kringelbach, 2008). 
Drugs use is initiated and sustained in large part by their hedonic (i.e., pleasurable) 
effects. Indeed, all major drugs of abuse activate the brain reward system, providing major 
motivation to obtain and consume addictive drugs (Kenny, 2007; Nesse and Berridge, 1997). 
In the beginning, liking the drug will be a sufficient motivation to use it. With time, there will 
be a shift in this motivation: a drug won’t be liked; it will be wanted, thus contributing to 
addiction (Robinson and Berridge, 2008). METH is a reward-related drug, which is why it is 
consumed by humans or self-administered by laboratory animals (Wise, 2009). There are 
different kinds of reinforcement that contribute to compulsive abuse of drugs. Positive 
reinforcement occurs when presentation of the drug increases the probability of a response 
to obtain the drug again. On the contrary, negative reinforcement occurs with mitigation of an 
existing aversive state or a drug-generated aversive state (e.g., withdrawal) (reviewed in 
Koob and Le Moal, 2001). 
The rewarding effects of drugs are caused by their ability to increase DA release in 
the nucleus accumbens (NAc) (Volkow et al, 2012). The amount of DA delivered to the NAc 
is directly involved in the hedonic component of reward (reviewed in Phillips et al, 2008). 
Resorting to behavioral studies, Schultz (2007) showed that DA projections to the striatum 
and frontal cortex also play a central role in mediating the effects of rewards on approach 
behavior and learning, providing evidence for a possible important role in learning and 
memory processes.  
After experiencing reward, an individual has the motivation to seek that same reward 
again. Environmental cues associated to a specific reward are meaningful reinforcing 
associations between reward and stimuli linked to that same reward. These cues are usually 
sufficient to initiate DA release by reward anticipation (Arias-Carrión et al, 2010). Concerning 
drug reward, the mesolimbic DA pathway [DA neurons in ventral tegmental area (VTA) 
projecting into NAc] appears to be the most relevant one (Wise, 2009). However, recent 
studies recognize the mesostriatal DA pathway [DA neurons in substantia nigra (SN) 
projecting into dorsal striatum] and the mesocortical DA pathway (DA neurons in VTA 
projecting into frontal cortex) to contribute to drug reward and addiction as well (Wise, 2009; 
3). 
Moreover, it is also known that D1 and D2-like receptors, respectively excitatory and 
inhibitory receptors for DA, are stimulated by amphetamines and might be involved in drug-
induced effects. D1 receptors are stimulated by large DA increases and are coupled to the 
Gs proteins, which activate adenylyl cyclase. D2 receptors are stimulated by relatively low 
DA concentrations and are coupled to Gi proteins, which inhibit adenylyl cyclase and activate 
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Figure 4. VTA–NAc reward circuit in rodents brain. Dopaminergic, glutamatergic and GABAergic 
connections to and from the VTA and NAc. Reward circuit includes dopaminergic projections from 
VTA to NAc, which release dopamine in response to reward-related stimuli, and GABAergic 
projections from NAc to VTA. Glutamatergic inputs control aspects of reward-related perception and 
memory. The dashed lines indicate internal inhibitory projections (adapted from Russo and Nestler, 
2013). 
 
K+ channels. Both receptor families are implicated in drug reward (Durieux et al, 2009; 
Missale et al, 1998; Vallone et al, 2000). 
Glutamatergic neurotransmission is also related with drug addiction. An increase in 
extracellular GLU might lead to excitotoxicity, due to increased activation of NMDAR and the 
consequent increase of intracellular Ca2+. METH induces increase of extracellular GLU in 
brain regions such as the VTA, the NAc, the prefrontal cortex and the striatum (reviewed in 
Cunha-Oliveira et al, 2008). It is believed that GLU modulates the reactivity of dopaminergic 
cells and dopamine release in NAc, regarding the reward effects of drugs of abuse (Kalivas 
and Volkow, 2005; figure 4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.7. Neuroinflammation associated to methamphetamine use 
As mentioned above, METH is capable of crossing the BBB and inducing its 
disruption. The CNS, when exposed to METH, shows damage in the BBB across all of its 
extent. However, hippocampus appears to be more sensitive to this deterioration, which 
causes proteins and ions to leak into the brain causing water to osmotically enter the brain 
parenchyma, generating brain edema. BBB disruption might involve METH-induced ROS 
production and hyperthermia, both of which are described to trigger BBB breakdown (Bowyer 
et al, 2008; reviewed in Marshall and O’Dell, 2012; Martins et al, 2011; Montagne et al, 2015; 
Sharma and Kiyatkin, 2009; Terrando et al, 2014). 
Inflammation is a response that has the purpose of repairing damages inflicted by a 
harmful agent (e.g., infection or traumatism). It is a complex response that involves cells, 
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plasma components and cellular products (Chavarria and Alcocer-Varela, 2004). It implicates 
the synthesis and release of proinflammatory mediators like cytokines and chemokines 
(O’Callaghan et al, 2008). Inflammation is considered a part of the innate immune system 
since it is a generic response to harmful stimuli (Abbas et al, 2012). 
In the CNS, microglial cells are involved in immune surveillance and are activated 
during neurodegenerative processes. They are recognized as being one of the fundamental 
components of an intrinsic brain immune system and are the major antigen-presenting cells 
in the brain. When activated by tissue injury, they release signaling molecules involved in 
inflammation, which may lead to neuronal damage. Moreover, microglia participates in 
shaping neuronal connectivity during development and in activity-dependent synaptic 
plasticity, neurogenesis, and learning (Kreutzberg, 1996; reviewed in Loftis and Janowsky, 
2014; reviewed in Salter and Beggs, 2014; Streit and Kincaid-Colton, 1995).  
Pro-inflammatory signaling is often involved in the dysfunction of the BBB’s structural 
and functional integrity (Abbott et al, 2006; Persidsky et al, 2006) and the inflammatory 
response by resident neuroglia, especially microglia, perpetuates BBB dysfunction, which in 
turn will increase the neuroinflammatory response (Petty and Lo, 2002). Disruption of the 
BBB caused by high-dose METH exposure is associated with neurodegeneration and 
activation of brain microglia and/or infiltration of macrophages. This will lead to immune 
dysfunction, with increased leukocyte/monocyte transmigration across the endothelium, and 
into the CNS, as well as increased invasion of peripheral bacteria and viruses into the brain 
(Buch et al, 2012; reviewed in Loftis and Janowsky, 2014; Ramirez et al, 2009).  
There are several studies reporting microglia activation in response to METH. For 
instance, Sekine et al (2008) described microglia activation in brains of METH addicts, 
especially in regions of dopaminergic and serotoninergic innervation. Gonçalves et al (2009) 
also reported microglia and astrocytes activation in the mouse hippocampi in response to 
METH administration. This activation is dose-dependent and may lead to an alteration of the 
peripheral and central immune functions (reviewed in Loftis and Janowsky, 2014; Thomas et 
al, 2004).  
It is also known that neurons are capable of producing inflammatory mediators and 
actively control microglia activity. Endangered or stressed neurons appear to emit signals of 
cytosolic or membrane origin leading to microglia activation (Streit, 2002). Neurons express 
“On” and “Off” signals to inform microglia about their status: “Off” signals are constitutively 
found in neurons and work by disappearance, meaning that when their production stops, 
microglia gets activated; whereas “On” signals are produced on demand and operate by 
appearance, in other words, their presence induces microglia activation. This new evidence 
shows that neurons, although vulnerable, may also have a rather active role in modulating 
mechanisms of microglial activation to maintain CNS integrity (reviewed in Biber et al, 2007). 
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Even slight alterations in the CNS homeostasis inform microglia, allowing these to provide 
defense against infection, injury and disease (Jurgens and Johnson, 2012). 
CNS immune mechanisms seem dependent of neuronal health and activity, indicating 
the importance of neurons in the regulation of immune cells (reviewed in Biber et al, 2007; 
Levite, 2008). Mott et al (2004) demonstrated that neurons must have functional axon 
terminals to inhibit microglia activation, pointing that physiologically intact neurons are 
necessary for regulating this activation. Besides, microglial cells express various receptors 
for neurotransmitters, neuropeptides and neuromodulators, showing that they have the 
capacity to sense neuronal activity (Pocock and Kettenmann, 2007). 
Moreover, METH-induced GLU release and, therefore, activation of GLU receptors 
results in a higher production of proinflammatory cytokines interleukin 1β (IL-1β), tumor 
necrosis factor (TNF) and interleukin 6 (IL-6). These cytokines can increase extracellular 
GLU levels by inhibiting GLU uptake or increasing GLU release from activated microglia, 
resulting in a cycle that contributes to neurotoxicity (reviewed in Yamamoto et al, 2010). 
In summary, it is known that microglia and astrocytes activation is a normal reaction 
to brain injury. However, excess neuroinflammation can lead to further brain damage. 
Repeated or high dose METH exposure induces alterations in glial and neuronal cell 
functions, which will contribute to a cascade of events, involving the production of cytokines 
and chemokines, and leading to neuroinflammation, neuronal damage and behavioral 
impairments (reviewed in Loftis and Janowsky, 2014). Neuroinflammation has a series of 
consequences in neurons, ranging from synaptic dysfunction to neuronal death. Beyond 
these, neurogenesis might become impaired which might contribute to dementia. Cognitive 
impairment is another consequence of neuroinflammation, since it has been described that 
both short and long term memory are affected by inflammatory factors (reviewed in Lyman et 
al, 2014). Neuroinflammation is also associated with neurodegenerative diseases such as 
Alzheimer’s disease, Parkinson's disease, Huntington's disease and multiple sclerosis, 
among others (Shabab et al, 2016). Furthermore, Narita et al (2006) has described that 
astrocyte activation in response to METH exposure results in the modulation of the reward 
mechanism, contributing for the rewarding effects caused by the drug.  
 
1.8. Influence of methamphetamine on gene expression 
The studies reporting METH-induced alterations on gene expression are abounding 
and diverse. The overall notion is that METH modifies gene expression, which will have 
consequences on cells and organisms. The study performed by Numachi et al (2004), for 
instance, reveals METH’s effect on DNA (Cytosine-5)-Methyltransferase-Like Protein 2 
(Dnmt2) mRNA in the hippocampus, which becomes decreased 24 hours after treatment. 
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The study mentions a previous work where it was also observed that DNA (Cytosine-5)-
Methyltransferase 1 (Dnmt1) mRNA in the hippocampus is decreased, 3 hours after acute 
METH treatment. Dnmt1 is a maintenance methyltransferase, involved in maintaining the 
preexisting methylation pattern of DNA, while Dnmt2 is involved in DNA methylation and 
might be involved in DNA repair, DNA recombination and carcinogenesis (Numachi et al 
2004). METH appears to be involved in chromatin modulation through epigenetic pathways 
(e.g. ΔFosB) which may contribute to amphetamine-induced neuronal plasticity and 
associative learning while also regulating sensitivity to repeated drug exposure (Kalda et al, 
2007; Renthal et al, 2008). 
A number of genes related to trafficking and protein turnover, metabolic pathways, 
transmitters, receptors and growth factors (cytokines) were shown to be upregulated in 
response to METH treatment. On the other side, some genes related to trafficking and 
protein turnover, modulators, effectors and intracellular transducers were decreased 
(Asanuma et al, 2004). Nikaido et al (2001) investigation revealed that expression of genes 
involved in circadian rhythms increased in the caudate-putamen of mice in response to acute 
METH treatment. Moreover, there is evidence of METH-induced activation of NF-κB, 
upregulation of TNF, increase of the expression and activity of matrix metallopeptidase 9 
(MMP-9) and reduction of tight junction proteins expression (Fernandes et al, 2014; Lee et al, 
2001; Martins et al, 2011; Ramirez et al, 2009).  
 
1.9. Objectives 
The understanding of the molecular mechanisms underlying METH neurotoxic effects 
will likely contribute to provide new therapeutic approaches. Having that in mind, we have 
recently conducted a RNA deep sequencing analysis to identify altered gene expression in 
both soma and neurites of hippocampal neurons exposed METH. The present research 
project starts at that point, analyzing the results of the RNAseq and aiming to identify genes 
that may become useful targets for future therapies. In particular, we have focused on genes 
that could be associated with the neuroinflammatory process that underlies addiction, since 
we have evidence that neuroinflammation may be associated with poor success in treatment 
and withdrawal attempts and may potentiate relapse. Therefore, we have selected genes 
involved in the neuron-glia interplay and have attempted to dissect the role of these 
candidates in METH-induced neuroinflammatory pathways. 
Our specific goals were: 
i) Select the candidates of interest related to neuroinflammatory pathways and 
neuron-glia interplay, which expression was shown to be altered in the soma of 
hippocampal neurons by METH administration; 
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ii) Evaluate gene and protein expression of the selected candidates, and select one 
candidate for further studies; 
 
iii) Functionally evaluate the role of the selected candidate, by modulating it 
expression in the presence of METH. 
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Chapter 2: Methodology 
2.1. Hippocampal neuronal cells culture  
The number of mice handled for this research was approved by the Institutional and 
National General Veterinary Board Ethical Committees according to National and European 
Union rules. Three- to six-month-old C57Bl/6 pregnant female mice were used for the 
hippocampal neuronal cultures (1 or 2 females for each neuronal culture). The animals were 
maintained under a 12 h light/dark cycle in type II cages in specific pathogen-free conditions 
(microbiological health status available). Animals were fed with regular rodents chow and tap 
water ad libitum. All animals used in this experiment were treated accordingly to Decreto-Lei 
113/2013, present in the Portuguese legislation. 
In order to obtain hippocampal cells cultures, we sacrificed wild-type pregnant 
C57BL/6 female mice at gestation day 16 by cervical displacement, performed by a qualified 
person to do so, in order to preserve molecular signaling in neurons. Embryos were removed 
from the female womb, and the intact brain was retrieved from the embryos and dissected to 
obtain the hippocampi. Hippocampi were isolated in Ca+-free and Mg2+-free Hank’s balanced 
salt solution (HBSS) (maintains the equilibrium (e.g., pH and osmotic concentration) needed 
for neurons survival). 
Neuronal cultures were prepared in a laminar flow cabinet. Hippocampi were 
dissociated with trypsin (0.25% in HBSS, for 10 minutes at 37ºC), washed in 10% fetal 
bovine serum diluted in HBSS (to stop trypsin activity), and washed in HBSS to remove 
serum (to prevent glia cells growth). Hippocampi were mechanically dissociated to separate 
individual cells from the connective tissue and maintained in serum free neurobasal medium, 
supplemented with B27 (1:50 dilution; Gibco), glutamate (25μM), glutamine (0.5mM), and 
gentamicin (0.12mg/mL) in poly-D-lysine (PDL) coated plates at a density of 9x104 cells/cm2 
on 6 well plates or 2x105 cells/cm2 on coverslips. Cultures were kept at 37°C in a humidified 
incubator with 5% CO2/95% air for 14 days in vitro (DIV). During the incubation period, 
cultures were regularly examined to make sure that cells were healthy and viable.  
METH (100µM) was added to the neurons at 14DIV, and cultures incubated for 
additional 24 hours at 37ºC 5% CO2/95% air. This METH dose was previously tested within a 
range of physiological doses in our laboratory following in vivo data from other authors 
(Fornai et al, 2004; Fornai et al, 2007), and we previously observed that, in our model, it 
does not affect neuronal death neither causes mitochondrial damage. 
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2.2. mRNA semi-quantification by real time PCR 
At 15 DIV, total RNA was extracted from neurons, in order to assess and validate the 
presence of the genes with altered expression. The extraction was achieved using TRIzol 
reagent with PureLink® RNA mini kit (Ambion by life technologies), according to the 
manufacturers’ instructions. Briefly, cells were scraped using 1mL of TRIzol® Reagent and 
incubated for 5 minutes. Chloroform (200µL) was added to the tube, shaken by hand for 15 
seconds and incubated at room temperature for 2-3 minutes. Samples were centrifuged at 
12,000 xg for 15 minutes at 4°C. The upper, colorless phase (≈ 400µL) containing the RNA 
was transferred to a fresh RNase-free tube, and an equal volume of 70% ethanol was added 
and samples were vortexed. Samples were then centrifuged at 12,000 xg for 15 seconds, at 
room temperature. Samples were washed 2 times for 15 seconds, at room temperature, and 
RNA was extracted in RNase-Free Water (30µL) by centrifugation at 12,000 xg for 2 minutes, 
at room temperature. 
RNA concentration was assessed with NanoDrop 1000 (Thermo Scientific), and RNA 
quality and integrity with Experion Automated Electrophoresis System (BioRad). Samples 
showing RNA degradation or contamination by DNA were discarded. Samples were kept at -
80ºC until further use. 
RT-qPCR is performed in two steps: reverse transcription and real time PCR. This 
means that reverse transcription and real time PCR are done in different tubes, with different 
optimized buffers, reaction conditions and priming strategies (Basic Principles of RT-qPCR, 
Thermo Fisher Scientific).  
cDNA synthesis was performed by reverse transcription using 1µg of the extracted 
RNA resorting to RT2 HT First Strand Kit (Qiagen), following manufacturers’ instructions. The 
obtained cDNA was stored at -20°C. 
Binding of Sybr green (iQTM SYBR® Green Supermix, Bio-Rad), a nucleic acid dye, to 
double stranded cDNA will emit fluorescence that will be used by the system to create a real 
time measurement of the amount of genetic material present. A higher amount of 
fluorescence detected means a higher amount of double-stranded cDNA. The lowest, but 
sufficient fluorescence detected will determine the threshold cycle (CT), later used to quantify 
the initial RNA concentration.   
To do so, we designed specific primers to the selected genes and to the reference 
genes (table I). Five genes (18s, Rpl19, Dcbld1, Rab7 and Ywhaz) were analysed to check 
their potential as reference genes. The chosen primers must hybridize with a specific region 
of the gene to avoid unspecific hybridization, and the amplicon (i.e., amplified region) should 
be between 75 to 200 base pairs long. For both amplicons and primers, the GC content 
should remain between 50% and 60%, regions with single-bases repeats should be avoided 
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and secondary structure formation ought to be avoided as well. In addition to these 
precautions, primers melting temperature should be maintained between 50°C and 65°C and 
G’s and C’s should be placed on ends of primers (Real-Time PCR Applications Guide, Bio-
Rad). Primers were designed using Beacon DesignerTM. 
 
Table I- Specific primers used on RT-qPCR . 
   Gene Primers 
Optn Forward 5’GGGCAATGAAGGAGATGAAG 3’ 
Reverse 5’TGGCTCACAGTCAGTTCT 3’ 
 
Olfm4 Forward 5’CTGCCAGTGTTCTGTTTC 3’ 
Reverse 5’CTTCTCCATGACCTCTACTC 3’ 
 
Rasgrp1 Forward 5’GCAGAGGTCTTCATCAAG 3’ 
Reverse 5’CAGCAGTTCAGTCATCTC 3’ 
 
RelB Forward 5’GAAGTCCACCAACACATC 3’ 
Reverse 5’CTGAACACCACGGATATG 3’ 
 
Ebf3 Forward 5’AGATTACGGCTTCCAGAG 3’ 
Reverse 5’GGTTATTGTGAGGCATCC 3’ 
 
18s Forward 5'AAATCAGTTATGGTTCCTTTGGTC 3' 
Reverse 5'GCTCTAGAATTACCACAGTTATCCAA 3' 
 
Rpl19 Forward 5’TAGGGAAGAGGAAGGGTA 3’ 
Reverse 5’AGGTACAGGCTGTGATAC 3’ 
 
Dcbld1 Forward 5’GTGACTGTCCTCTTCAAG 3’ 
Reverse 5’CTCCTGCTATGTCTCTAC 3’ 
 
Rab7 Forward 5’CACAATAGGAGCGGACTT 3’ 
Reverse 5’CACCAGAACACAGCAATC 3’ 
 
Ywhaz Forward 5’GATGAAGCCATTGCTGAACTTG 3’ 
Reverse 5’GTCTCCTTGGGTATCCGATGTC 3’ 
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RT-qPCR was performed in METH-treated vs non-treated neurons in order to confirm 
the differential expression of the selected candidates. The samples were prepared 
accordingly to table II and the protocol used is described in table III. qPCR is executed in iQ5 
Multicolor Real-Time PCR Detection System (Bio-Rad). 
 
Table II- qPCR Reaction Setup (adapted from iQ
TM 
SYBR
®
 Green Supermix).  
Component Volume per 20µL reaction Final Concentration 
iQTM SYBR® Green Supermix 10µL 1x 
Forward and Reverse Primers Variable 200nM 
DNA Template 1µL 1µg 
H2O Variable - 
Total reaction mix volume 20µL - 
 
 
 
 
 
 
 
 
 
 
 
 
 
Il-1β Forward 5’GCCCATCCTCTGTGACTCAT 3’ 
Reverse 5’AGGCCACAGGTATTTTGTCG 3’ 
 
TNF Forward 5’CTCACACTCAGATCATCTTC 3’ 
Reverse 5’GAGAACCTGGGAGTAGATAAG 3’ 
 
iNOS Forward 5’GTGGTGACAAGCACATTTGG 3’ 
Reverse 5’AAGGCCAAACACAGCATACC 3’ 
 
Il-6 Forward 5’CACAAGTCCGGAGAGGAGAC 3’ 
Reverse 5’CAGAATTGCGATTGCACAAC 3’ 
 
TGF-β Forward 5’TGAGTGGCTGTCTTTTGACG 3’ 
Reverse 5’GTTTGGGACTGATCCCATTG 3’ 
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Figure 5. Livak and Pfaffl quantification methods. Formulas used to quantify qPCR results. 
Table III- qPCR Reaction Protocol.  
                                         Temperature Duration 
Cycle 1 (1x) 94.0°C 03:00 
Cycle 2 (40x) --- --- 
*Step 1 94.0°C 00:15 
*Step 2 60.0°C 00:20 
Cycle 3 (81x) 55.0°C - 95.0°C 
Increase set point 
temperature after cycle 2 by  
0,5 °C 
00:30 
 
 
cDNA quantification may be absolute or relative, calculated through various 
processes. In this case, quantification was relative, using both Livak and Pfaffl methods for 
efficiency correction. Relative quantification was performed by comparing the target gene 
expression to the reference gene expression, in both control and treated conditions. Livak 
method assumes that both target and reference genes are amplified with efficiencies near 
100% and within 5% of each other, while Pfaffl method assumes that each gene has the 
same amplification efficiency in treated and control samples, but it is not necessary that the 
target and reference genes have the same amplification efficiency (Real-Time PCR 
Applications Guide, Bio-Rad; figure 5). Results were normalized using one reference gene 
out of the five tested.  
 
 
 
 
 
 
2.3. Protein extraction and western blot analysis  
Proteins being translated for the genes confirmed to have a differential expression in 
neurons treated with METH vs non-treated neurons were evaluated by western blot, using 
specific antibodies.  
Protein extraction was performed at 15DIV. Neurons were washed with ice-cold PBS 
(twice) and lysed with RIPA (150mM NaCl, 50mM Tris–HCl, pH 7.4, 5mM EGTA, 1% Triton, 
0.5% DOC and 0.1% SDS at a final pH 7.5), supplemented with 50mM sodium fluoride 
(NaF), 1.5mM sodium orthovanadate (Na3VO4), 1mM dithiothreitol (DTT) and a cocktail of 
protease inhibitors (0.1mM phenylmethylsulfonyl fluoride (PMSF), CLAP (1μg/ml 
Livak Method: 2–∆∆CT 
Pfaffl Method:  Ratio=
(E 
target
)
∆Ct, target(calibrator-test)
(E
 ref
)
∆Ct, ref(calibrator-test)
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chymostatin, 1μg/ml leupeptin, 1μg/mL antipain, 1μg/mL pepstatin; Sigma).  Protein extracts 
were kept at -80ºC until further use.  
Protein was quantified using the Bicinchoninic acid (BCA) method, and samples were 
denaturated using 5x denaturating buffer (625mM Tris, pH 6.8, 10% SDS, 500mM DTT, 50% 
glycerol and 0.01% bromophenol blue), added to a 1x final concentration and boiled at 95ºC 
for 10 minutes.   
Protein expression was analysed by Western Blot, using 40µg of sample, loaded into 
a 10% SDS-page gel, that runs at 60V (stacking gel) and 80V (resolving gel). The ladder 
used was PageRuler™ Plus Prestained Protein (Thermo Fisher Scientific). Proteins were 
transferred into a PVDF membrane using Trans-Blot® Turbo™ Transfer System (Bio-Rad). 
Membranes incubated with primary antibody overnight, at 4°C (anti-Olfm4 1:1000, D6Y5A, 
kindly provided by Cell Signaling; anti-GAPDH 1:100000, 5G4 HyTest; anti-Laminin 1:1000, 
ab7463 Abcam; anti-β1 Integrin 1:3000, ab52971-100 Abcam; anti-ZO-1 2µg/mL, 40-2200 
Invitrogen; anti-Claudin-5 1:1000, ab53765 Abcam; anti-pSrc 1:1000, #6943S Cell Signaling; 
anti-Src 1:5000, ab109381 Abcam), and with secondary antibody for 1 hour, at room 
temperature (HRC conjugated anti-rabbit 1:10000, A0545 Sigma-Aldrich; HRC conjugated 
anti-mouse 1:3000, 31432 Thermo Fisher Scientific). Membrane revelation resorted to 
Clarity™ Western ECL Substrate (Bio-Rad) and to ChemiDoc (ChemiDoc™ MP System, Bio-
Rad). Results were quantified and processed with ImageLab software (Image Lab™ 
Software, Bio-Rad).  
 
2.4. Immunocytochemistry 
Protein expression in cultured hippocampal neurons was also analysed by 
immunocytochemistry. At 15DIV, neurons cultured in coverslips were fixed with 4% 
paraformaldehyde and 4% sucrose in PBS, permeabilized with 0,25%Triton X-100 in PBS for 
10 minutes at room temperature, and blocked with 5% BSA in PBS with 0,1%Tween-20 for 1 
hour at room temperature. Neurons incubated with primary antibody (anti-Olfm4 1:50, 
D6Y5A, kindly provided by Cell Signaling; anti-ZO-11:100, 40-2200 Invitrogen; anti-claudin-5 
1:100, ab53765 Abcam; anti-pSrc 1:100, #6943S Cell Signaling; anti-β3 tubulin 1:1000, 
G7121 Promega; anti-GFP 1:500, 11814460001 ROCHE Sigma-Aldrich) diluted in 0.5% BSA 
in PBS-0,1%Tween-20 overnight, at 4°C. Secondary antibodies (Alexa 594 anti-rabbit 1:500, 
A11012 Life Technologies; Alexa 488 anti-mouse 1:500, A11001 Life Technologies; Alexa 
488 anti-rabbit 1:500, #4412S Cell Signaling; Alexa 568 anti-mouse 1:500, A11004 Life 
Technologies) were incubated for 1 hour, at room temperature. Hoechst 33342 (0.5µg/mL; 
B2261 Sigma-Aldrich) was used as a nuclear marker, and incubated with neurons for 10 
minutes, at room temperature. Coverslips were mounted in Fluorescence Mounting Medium 
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(DAKO) and imaging was performed using Leica DMI 6000 Widefield microscope. Images 
were quantified using image analysis software FIJI. 
  
2.5. Zymography to assess MMP2 and MMP9 activity 
MMP2 and MMP9 activity was evaluated using a gelatin zymography assay. Briefly, 
30µg of protein was mixed with sample buffer (10% SDS, 120mM sucrose, 0.25M Tris 
pH6.8); 1µL of buffer per 2µL of sample. Samples were loaded into a gelatin acrylamide gel 
(resolving gel: 10% polyacrylamid gel with 0.1% gelatin as a substrate; stacking gel: 5% 
polyacrylamide gel) that runs at 80V, at room temperature. After running, SDS was removed 
from the gel with a washing solution (2% Triton X-100) and incubated, overnight, at 37°C, 
with MMP substrate buffer (40mM Tris, 10mM CaCl2.(2H2O), 3mM NaN3 in ultrapure H2O 
until 1000mL, pH7.5). Gel was then stained with Coomassie blue solution (1.2mM in a 10% 
acetic acid and 40% methanol solution) for 20 minutes and destained (20% methanol, 10% 
acetic acid, in distilled H2O) until bands were visible. 
 
2.6. FRET assay 
FRET was performed to detect c-Src activity in response to METH exposure as well 
as calcium accumulation in endoplasmic reticulum and RhoA activation. This technique relies 
on probes with two kinds of fluorophores: the donor and the acceptor. When excited with the 
adequate light, donor emits energy that excites the acceptor fluorophore which then emits 
detectable fluorescence. This only occurs when donor and acceptor fluorophores are in close 
proximity (figure 6). 
In order to do so, we plated neuronal cells (9x104 cells/cm2) on culture dishes (µ-Dish 
35mm, iBidi) that were transfected (as detailed below) with FRET probes for c-Src activation 
(K Ras Src YPet; Ouyang et al, 2008), for calcium present in the endoplasmic reticulum 
(D1ER; Palmer et al, 2004) or RhoA activation (Raichu-RhoA; Yoshizaki et al, 2003). 
Images were obtained with Leica DMI6000B Widefield inverted microscope with a 
mercury metal halide bulb as excitation light source, integrated with EL6000 light attenuator. 
High-speed low-vibration external excitation/emission filter wheels (equipped with CFP/YFP 
excitation and emission filters) were mounted on the microscope (Fast Filter Wheels, Leica 
Microsystems) and a 440–520 nm dichroic mirror (CG1, Leica Microsystems) and a PlanApo 
63x1.3NA glycerol immersion objective were used for acquiring donor (CFP) and acceptor 
(FRET) images. Images were acquired using 2x2 binning and a digital CMOS camera 
(ORCA-Flash4.0 version 2, Hamamatsu Photonics). At each time point, donor and FRET 
images were sequentially acquired using different filter combinations (donor excitation plus 
donor emission, and donor excitation plus FRET emission, respectively).  
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Figure 6. FRET assay. Schematic explaining FRET mechanism. When excited, donor emits energy 
that, when in proximity, excites the acceptor fluorophore which then emits detectable fluorescence 
(adapted from Lindquist and Niesner, 2015). 
Obtained images were analysed resorting to FIJI image analysis software. 
Background was subtracted from all slices, in both channels, using a Kalman filter 
implementation. Segmentation was achieved on a pixel-by-pixel basis using the local 
Phansalkar algorithm. After background subtraction and filtering, ratiometric images 
(Donor/FRET for c-Src probe, FRET/Donor for the ER calcium release probe or FRET/Donor 
for RhoA probe) were generated in intensity-modulated display mode using the FRET 
images as intensity modulators in FIJI (Socodato et al, 2015). 
 
 
 
 
 
 
 
 
 
 
2.7. Gene expression modulation 
The vector of interest (shRNA.Olfm4) was acquired from VectorBuilder (Cyagen) 
(target sequence: AGGAGTATGTCCAGCTAATAA). We used, as a control, DsRed vector in 
infected neurons or Venus vector in transfected neurons. 
To produce the plasmid DNA, bacteria were plated in AGAR-ampicillin (100µg/mL) 
plates and incubated overnight, at 37°C. After the incubation period, one single colony was 
collected and pre-inoculated in LB-medium (5mL), supplemented with ampicillin, that 
incubates at 37°C, with agitation, for approximately 12 hours. Bacteria were then diluted in 
150mL of LB-medium supplemented with ampicillin, which incubates overnight, at 37°C, with 
agitation. Afterwards, the medium was centrifuged in order to pellet bacteria. NucleoBond® 
Xtra Midi/Maxi kit (Macherey-Nagel) was used to purify the plasmid DNA, following 
manufactures’ instructions.  
Lentiviruses production was performed in HEK293 cell line transfected with 
jetPRIME® (Polyplus-transfection), following manufactures’ instructions. Plasmid DNA (10µg) 
was diluted in jetPRIME® buffer and vortexed for 10 seconds. jetPrime®  reagent was added 
and vortexed for 10 seconds. After incubating at room temperature, for 10 minutes, the 
transfection mix was added to the cells After 24 hours, the medium was collected, 
centrifuged at 3000rpm for 15 minutes, at 4°C, and the supernatant was recovered and 
aliquoted and stored at -80°C. 
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2.7.1.    Neuronal infection with lentivirus 
For the knockdown gene expression experiments, cultured hippocampal neurons 
were infected at 11 DIV. For that, ¼ of the viral suspension diluted in culture conditioned 
medium was added to the neurons and, after 24 hours, this medium was replaced by culture 
conditioned medium. At 14 DIV, neurons were treated with METH 100µM for 24 hours, and 
protein was extracted for western blot analysis as described above. 
 
2.7.2. Neuronal transfection  
To knock-down gene expression in neurons we also used transfection by calcium 
phosphate co-precipitation method at 12 DIV. 
To do so, 100µL of precipitate (enough for two 10mm coverslips) was prepared by 
diluting 4µg of plasmid DNA in 1x TE buffer (10mM Tris-HCl pH 7.5, 1mM EDTA pH 8.0, pH 
7.3) in a final volume of 45 µL. 5 µL of 2.5M CaCl2 (prepared in 10mM HEPES) was added 
dropwise to the TE/DNA mixture (final concentration of 250 mM); the mix was gently 
vortexed. The DNA/ TE/ CaCl2 solution was added, dropwise, to 50µL of 2x HEBS solution 
(0.4mM NaCl, 10mM KCl, 1.4mM Na2HPO4, 11mM Dextrose, 84mM HEPES, pH 7.2). The 
precipitate was then developed at room temperature for 30 minutes, protected from light, and 
vortexed every 5 minutes. In the meantime, each coverslip was placed in a well containing 
200µL of conditioned medium and 50µL of 10mM kynurenic acid, to a final concentration of 2 
mM, and cells were returned to the 37ºC/5% CO2 incubator. When ready, precipitate (50µL) 
was added, dropwise, to the each coverslip, and cells were incubated for, approximately, 3 
hours. Then, neurons were incubated with 1mL of HCl-acidified 2 mM kynurenic acid and 
cells returned to the incubator for 20 minutes. Finally, coverslips were transferred to the 
original wells, containing their conditioned medium. At 14 DIV, cells were exposed to METH 
(100µM) for 24 hours, and neurons were fixed as described above. 
 The same procedure was used to express Venus (i.e., control vector) and a 
constitutively active form of RhoA (RhoA CA). 
2.8. Morphological Analysis 
 To evaluate neuronal morphology, we assessed neurite length and branching as 
morphological characteristics. Neurite length was assessed using FIJI (Schindelin et al, 
2012) software and the plugin NeuronJ (Meijering et al, 2004) by tracing neurites in neurons 
transfected with either Venus or RhoA CA, in control and exposed to METH neurons. The 
obtained data was analysed for neurite length and was used to evaluate neuronal branching 
by Sholl Analysis. For this, we resorted to MATLAB (MATLAB 6.1, The MathWorks Inc., 
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Natick, MA, 2000) software, Bonfire Program (Langhammer et al, 2010) and NeuronStudio 
(Wearne et al, 2005) that allow us to draw concentric circles around the cell body (6 µm 
apart) and determine the number of intersections between the circles and neurites. 
 
2.9. Statistical Analysis 
The results obtained in each experiment were normalized by the control mean. Data 
is presented as mean ± SEM of at least three different experiments, performed in 
independent preparations. Statistical analysis of the results was performed using GraphPad 
Prism7, using Student’s t test or One-way analysis of variance (ANOVA), followed by 
adequate post-tests.   
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Chapter 3: Results 
3.1. Selection of Candidates 
The data supporting this work was obtained in previous experiments, performed in 
our laboratory, involving an RNA sequencing approach to assess genes showing altered 
expression in cultured hippocampal neurons, in response to METH exposure. RNA was 
extracted from soma and neurite fractions of hippocampal neuronal cultures exposed, or not, 
to METH (Pertz et al, 2008). RNA sequencing, as the name points, is the transcriptome (i.e., 
all transcribed RNA) profiling through deep-sequencing technologies. It provides, for 
example, information about gene transcriptional structure and expression levels of transcripts 
during development and under different conditions (Wang et al, 2009). In this particular 
research, it granted valuable information on how METH might be altering gene expression.  
Because METH was previously seen to affect the morphology of hippocampal 
neurons, and taking into consideration that it is now accepted that changes in neuronal 
morphology are strongly associated with the addictive behaviors, the hippocampus was the 
brain region selected for this study (Thompson et al, 2004). Beyond this, it is also known that 
neurodegeneration associated to METH-use is noticeable in brain regions with notable IgG 
immunoreactivity (i.e., hippocampus and amygdala) and during hyperthermic conditions 
(mouse body temperatures >40.5 °C). It was described that the effect of both BBB disruption 
and hippocampal damage might be sufficient to compromise cognitive function (Bowyer and 
Ali, 2006). Besides, the hippocampus is described as being part of the reward mechanism, 
since it is involved in long-term episodic memory, contributing to reward-related behaviors 
(e.g. reinforcement learning or reward-guided motivation) (Davachi, 2006; Davidow et al, 
2016; Squire et al, 2004).  
The obtained results were first analysed through a bioinformatics approach in order to 
identify the genes differentially expressed in neurons exposed to METH vs non-exposed 
neurons, in the soma fraction. This analysis was outsourced to the Brabaham Bioinformatics 
Centre (Cambridge, UK). From this analysis we have identified 128 genes with altered 
expression when exposed to METH. Each of these genes was thoroughly analysed recurring 
to information available in multiple sources, from scientific articles to databases (Genecards, 
NCBI and Uniprot), and classified according to four categories, based on their function: 
metabolism, cell signaling, cell cycle or transcription/transduction. From this analysis we 
have selected 5 genes that were likely to be related to neuroinflammation and neuron/glia 
interplay: Optn, Olfm4, Rasgrp1, RelB and Ebf3. These genes showed a differential 
expression in the soma of METH treated vs non-treated hippocampal neurons: the first two 
genes were upregulated, and the last three were downregulated in the soma of neurons 
exposed to METH (table IV). Besides the function of these selected genes, we also took into 
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consideration how altered the mRNA expression was, how the selected proteins affect the 
cerebral function and how it would be relevant towards METH addiction. Since the selected 
genes have either a direct or indirect link to inflammatory mechanisms, they might also alter 
neuroinflammatory pathways and physiological responses. 
The Rasgrp1 gene translates into the RAS Guanyl Releasing protein (90 kDa), that is 
responsible for activating Ras proteins, through switching bound GDP for GTP. 
Overexpression of this protein results in increased activation of Ras proteins. Rasgrp1 is also 
responsible for activating the Erk/MAP kinase pathway and regulating the development, 
homeostasis and differentiation of T and B cells. (Hartzell et al, 2013; RASGRP1. Available 
from: http://www.genecards.org/cgi-bin/carddisp.pl?gene=RASGRP1&keywords=rasgrp1). 
The RelB gene encodes the RelB Proto-Oncogene protein (62 kDa), a NF-κB subunit. 
It belongs to the NF-κB transcription factor family and it can both activate and repress the 
NF-kB complex, through interactions with RelA. It controls dendritic cells maturation and may 
be used as a therapeutic target to manipulate T cells response (Marienfeld et al, 2003; Shih 
et al, 2012). 
The Ebf3 gene encodes the Early B-Cell Factor 3 (65 kDa) which belongs to the EBF 
transcription factors family and is involved on B cells differentiation, bone development and 
neurogenesis. It has been suggested that this protein might act as a tumor suppressor, since 
its expression is silenced in brain tumors. Microglial cells activation, usually occurring in 
neuroinflammation and neurodegenerative diseases, leads to a decrease on Ebf3 expression 
on mice hippocampus (Lee et al, 2013; Zhao et al, 2006; EBF3. Available from: 
http://www.genecards.org/cgi-bin/carddisp.pl?gene=EBF3).  
The Optn gene encodes for Optineurin (66 kDa), which is, composed of multiple 
coiled-coil domains, an ubiquitin-binding domain and a C-terminal zinc finger. This protein is 
involved in Golgi complex maintenance, membrane trafficking and exocytosis. It has been 
identified as a negative regulator of NF-kB signaling and it was hypothesized that it uses TNF 
or Fas-ligand pathways to modulate apoptosis, inflammation or vasoconstriction. It was also 
described that optineurin is overexpressed in response to viral infections (Nakamura et al, 
2014; Sudhakar et al, 2009; OPTN. Available from: http://www.genecards.org/cgi-
bin/carddisp.pl?gene=OPTN; Q96CV9 (OPTN_HUMAN). Available from: 
http://www.uniprot.org/uniprot/Q96CV9#section_comments).  
The Olfm4 gene translates into Olfactomedin4 protein (57 kDa), a matrix glycoprotein 
that belongs to the olfactomedin domain-containing protein family. It has been described as 
an anti-apoptotic factor, being preferably expressed in non-neuronal tissues, like the 
gastrointestinal tract and bone marrow.  Olfm4 expression is known to be regulated by 
granulocyte colony-stimulating factor (G-CSF), transcription factor PU.1 (PU.1) and NF-κB, 
and has been linked to inflammatory processes, since deleting this gene increases immune 
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defense against Staphylococcus aureus (Liu et al, 2010; Liu et al, 2013; Tomarev and 
Nakaya, 2009; Zhang et al, 2002). It has been pointed that Olfm4 interacts with matrix 
metalloproteinases (MMP9) and integrins, and that it is also involved in cell adhesion and 
tumor metastasis (Park KS et al, 2012). 
 
Table IV- mRNA expression in response to METH exposure. Log2FoldChange reveals if METH 
causes an increase or a decrease in gene expression.  
Gene Base Mean log2FoldChange* P value* 
Rasgrp1 998,487 -0,371 0,045 
RelB 341,187 -0,538 0,031 
Ebf3 88,840 -0,799 0,020 
Optn 1286,724 0,296 0,041 
Olfm4 213,093 0,610 0,018 
 
*Results extracted from the RNAseq analysis outsourced to Brabaham Bioinformatics Centre 
(Cambridge, UK)  
 
3.2. mRNA expression levels evaluated through RT-qPCR 
In order to validate the data obtained in our RNAseq analysis, and evaluate the 
mRNA expression levels of the selected candidates (Optn, Olfm4, Rasgrp1, RelB and Ebf3), 
cultured hippocampal neurons were treated, or not, with METH for 24 hours, and total RNA 
was extracted. mRNA levels were assessed by reverse transcription quantitative PCR and 
quantification was performed using the expression of a reference gene. The identification of 
the appropriate reference gene is of crucial relevance to this step, since it is an internal 
reaction control whose expression levels are unaffected by experimental factors (reviewed in 
Kozera and Rapacz, 2013). For that, we tested several genes to assess if they could be used 
as reference genes. The genes Rpl19, Dcbld1 and Rab7 were selected from the RNAseq 
analysis, as genes whose expression levels were not differentially affected in neurons 
exposed or not to METH. Moreover, we also used Ywhaz (Tyrosine 3-Monooxygenase; 
belongs to the 14-3-3 family of proteins that mediate signal transduction by binding to 
phosphoserine-containing proteins and regulates several general and specialized signaling 
pathways; Ywhaz. Available from: http://www.genecards.org/cgi-
bin/carddisp.pl?gene=YWHAZ), a gene that was previously described in our lab as a gene 
whose expression is not altered by METH administration, and 18S, a gene widely used as a 
reference gene. We end up selecting the Ywhaz gene, since this was the only that showed 
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no significant difference (i.e. a difference equal or smaller than 1 amplification cycle in qPCR) 
between neurons treated or not with METH. We quantified gene expression using two 
quantification methods (Livak and Pfalff) (Real-Time PCR Applications Guide, Bio-Rad). 
The results previously obtained in the RNA sequencing, as referred in section 3.1 
(see Table I)  showed that Ebf3, Rasgrp1 and RelB had a decreased expression in the soma 
of neurons exposed to methamphetamine versus non-exposed neurons, while Optn and 
Olfm4 presented an increased expression. Using RT-qPCR, we observed that the gene 
expression levels of Rasgrp1, RelB and Ebf3 were not significantly altered in neurons treated 
with METH versus non-treated neurons, which may relate to the fact that we evaluated 
mRNA extracted from the entire neuron, while the RNAseq analysis only evaluated soma. 
We could not evaluate the expression of the Optn gene, since the amplification was not 
successful (figure 7).    
As displayed in Table I, Olfm4 mRNA expression was seen to be significantly 
increased in hippocampal neurons exposed to methamphetamine comparing to non-exposed 
neurons in our RNAseq analysis. As represented in figure 8 we confirmed that upon 
exposure to METH the Olfm4 mRNA expression levels were significantly increased in 
primary cultures of hippocampal neurons (figure 8, p<0.05 as obtained through unpaired t-
testing). Based on these results we further investigated the putative role of Olfm4 under 
exposure to psychostimulants. 
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Figure 7. qPCR results for Rasgrp1 (A), RelB (B) and Ebf3 (C) genes. No differences could be 
observed for the gene expression levels of Rasgrp1 (A), RelB (B) and Ebf3 (C) when comparing mRNA 
obtained from hippocampal neurons exposed to methamphetamine with that of control cultures.. 
Quantification was executed resorting to Livak and Pfaffl methods. The results are presented as the 
mean ±SEM of 3 (A and C) or 5 (B) independent experiments. Statistical analysis was performed using 
an unpaired t-test. 
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Figure 8. Olfm4 mRNA increased expression levels under methamphetamine exposure. We 
observed a significant increase for the gene expression levels of Olfm4 when comparing mRNA 
obtained from hippocampal neurons exposed to methamphetamine with that of control cultures. 
Quantification was executed resorting to Livak and Pfaffl methods. The results are presented as the 
mean ±SEM of 3 independent experiments. Statistical analysis was performed using an unpaired t-test. 
The results are the average of ±SEM of 3 independent experiments performed in independent 
experiments. Statistical analysis was performed using an unpaired t-test with Welch’s correction. 
*p<0.05 
 
 
 
 
 
 
 
 
 
 
  
 
3.3. Olfm4 expression levels in hippocampal neuronal cultures 
Next, we evaluated the effect of METH in the protein expression levels of Olfm4. In 
order to do so, we produced protein extracts from cultured hippocampal neurons exposed or 
not to METH 100 µM for 24 hours, and analysed them by western blot. Of note, Olfm4 
protein levels were decreased in response to METH exposure (figure 9B, p<0.05), which was 
not in accordance with the expected results considering that the mRNA expression levels of 
Olfm4 were increased both in the RNAseq analysis and the qPCR. Mouse gut extract was 
used as a positive control, since Olfm4 is highly expressed in this tissue (Tomarev and 
Nakaya, 2009; Zhang et al, 2002) (figure 9A).  
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Figure 9. Olfm4 protein expression in hippocampal neurons. (A) Evaluation of Olmf4 protein 
levels in gut extract and hippocampal extract used as positive controls, and in neuronal cultures. 
(B) Protein extracts from hippocampal neuronal cultures analysed by western blot using an antibody 
for Olfm4, weight is defined as 70kDa. Representative images of control (C) vs Methamphetamine 
(100µM) (D) 15 DIV hippocampal neuronal cultures showing an immunocytochemistry using an 
antibody against Olfm4 (green) and the nuclear marker Hoescht (blue). Images were obtained using 
a Leica DMI 6000 Widefield microscope and quantified (D) using image analysis software FIJI. 
Columns represent mean ±SEM for 3 independent experiments performed in different preparations 
and were analysed using a paired t-test. *p<0.05  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.4. Finding a putative role for Olfm4 in hippocampal neurons 
The primary goal of this work was to assess if METH administration to the cultured 
hippocampal neurons would affect the expression of genes that could be involved in the 
modulation of inflammation. The first issue addressed was if we could detect mRNA levels by 
RT-qPCR of a series of elements usually associated with inflammation in neurons: interleukin 
(IL)-1β, TNF, inducible nitric oxide synthase (iNOS), IL-6 and tumor growth factor (TGF)-β. 
IL-1β is a pro-inflammatory cytokine, which has been described as a vital regulator of acute 
central nervous system inflammation. Expressing IL-1β is sufficient to cause a continued 
neuroinflammatory response, within the mouse hippocampus (Ramesh et al, 2013; Shaftel et 
al, 2007).  TNF is a pro-inflammatory cytokine involved in starting and sustaining 
inflammatory responses (Belarbi et al, 2012). iNOS is expressed in neurons in response to a 
complex signaling cascade, causing iNOS-dependent nitric oxide generation, neuronal 
E C 
Olfm4 
Hoechst 33342 
D 
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dysfunction and eventually death (Heneka and Feinstein, 2001; Olivenza et al, 2000). IL-6 is 
also a pro-inflammatory cytokine produced by neurons is response to injury-related stimuli 
and is elevated in inflammatory states (Murphy et al, 1995). It is described as a pleiotropic 
cytokine since it is involved in several biological functions, such as immune regulation, 
hematopoiesis and oncogenesis (Kishimoto, 2010). Finally, TGF-β, an anti-inflammatory 
cytokine, regulates proliferation, differentiation, adhesion, migration, among other cellular 
processes. It is believed that it might contribute to diminish microglia activity in particular 
circumstances (reviewed in Biber et al, 2007; Brionne et al, 2003; Available from: 
http://www.genecards.org/cgi-bin/carddisp.pl?gene=TGFB1). 
Interestingly, although METH is described to induce neuroinflammation and neuronal 
cells are said to express the inflammatory elements above mentioned, we could not 
successfully amplify none of the genes coding for such elements, when using mRNA 
collected from hippocampal cultures exposed to METH and respective controls, which might 
indicate that neurons do not produce such factors in direct response to METH. For that 
reason, we could not further explore the possible relation of Olfm4 with the expression of 
these proteins/cytokines. 
Olfm4 is, as already mentioned, a matrix glycoprotein. Several studies indicate that 
this protein is involved not only in neuroinflammatory processes, but also in extracellular 
matrix remodeling. Therefore, we decided to evaluate how METH was affecting relevant 
matrix proteins in our hippocampal cultures.  It has been described that Olfm4 interacts with 
integrins (Parks et al, 2012), lectins and cadherins (Tomarev and Nakaya, 2009). With this in 
mind, we evaluated the effect of METH treatment (100 µM for 24 hours) in the expression 
levels of β1 Integrin (ITGB1), Laminin, Claudin5 (Cldn5) and Zonula occludens-1 (ZO-1), by 
western blot analysis. For both β1 Integrin and Laminin no detectable bands were present at 
the expected molecular weight when using adequate antibodies. For the expression levels of 
Cldn5 (Fig 10A) and ZO-1 (Fig 10B) no significant differences were observed in neurons 
treated with METH versus non-treated neurons. Of note, our laboratory recently reported that 
exposure to METH leads to translocation of Cldn5 from the membrane to the cytoplasm in an 
endothelial cell line, which was accompanied by a significant reduction of total Cldn5 
expression (Fernandes et al, 2016), although this does not seem to be the case in our 
hippocampal cultures, we will further address this issue in chapter 3.5. 
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Figure 10. Claudin5 and ZO-1 protein levels in hippocampal neuronal cultures. Methamphetamine 
(100 µM) does not significantly affect the expression of either Claudin5 (A) or ZO-1 (B) in primary 
hippocampal cultures when compared to control conditions. GAPDH was used as a loading control. 
Columns represent mean ±SEM 3 independent experiments performed in independent experiments 
and were analysed using a paired t-test. *p<0.05 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In endothelial cells, our laboratory has also reported METH-exposure increases the 
expression of MMP9 by increasing the expression of ILK (Integrin Linked Kinase) affecting 
cytoskeletal integrity (Fernandes et al, 2016). MMPs are zinc-containing endopeptidases, 
that, when activated, participate in the regulation of diverse physiological and pathological 
processes like the degradation of extracellular matrix, remodeling of tissues or shedding of 
cell surface receptors. MMPs are also involved in brain development, affecting several 
neurophysiological functions, like synaptic plasticity and long-term potentiation (reviewed in 
Brkic et al, 2015). 
 Src family proteins are involved in modulating MMPs (in particularly MMP2) 
activation through the ERK/Sp1 pathway (Kuo et al, 2006). More specifically, increased Src 
activation enhances the binding of Sp1 transcription factor leading to gene transcription (Kuo 
et al, 2006). MMPs are proteolytic zinc-containing endopeptidases that degrade ECM 
proteins. They are secreted into the extracellular milieu or 
expressed in the plasma membrane (reviewed in Mulholland et al, 2016). 
Bearing this in mind, we decided to determine if Src activation (i.e. Src 
phosphorylation, pSrc) was affected in hippocampal neurons by METH exposure. To do so, 
total Src and pSrc protein expression levels were analysed by western blot and results were 
B 
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Figure 11. pSrc expression in METH exposed hippocampal cultures. Total amount of pSrc vs 
total Src determined by Western blot. Data represent mean ±SEM for 3 independent experiments 
performed in different preparations. Statistical analysis was performed using a paired t-test.  
normalized for total Src levels. As represented in figure 11, at the tested level, we could not 
observe a significant difference between control and METH exposed conditions.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
As the western blot results reflect a 24h time point after the exposure to METH, we 
further assessed Src activity under METH, conducting a FRET analysis in hippocampal 
neurons, to evaluate c-Src activation in response to METH exposure in real time (figure 12). 
As represented in figure 12A, c-Src activity increases in response to METH exposure, 
displaying a late-start (10 min delay) but steady and prolonged effect.  Because calcium 
influx has been previously linked to Src activation (Rusanescu et al, 1995), we also 
conducted a FRET assay to measure the amount of calcium release by the endoplasmic 
reticulum (ER) (figure 12B). We observed that approximately 5 min after METH 
administration, the calcium present in the ER starts decreasing up to 20 minutes. At 20 
minutes after METH administration, calcium levels rise and start decreasing shortly after, in a 
way that is compatible with a cycling function. Importantly, the augment in calcium release 
seems to correlate with the augmented c-Src activity observed.   
 
 
 
pSrc 60kDa 
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Figure 12. FRET analysis for c-Src activity and release of Calcium from the endoplasmic 
reticulum. (A) Primary hippocampal neurons expressing a c-Src FRET probe (K Ras Src YPet) were 
challenged with 100μM METH. Donor/FRET emission ratios before (control; t=0 in the images) and 
after METH administration were normalized at 0 min. Symbols represent the mean + SEM of two 
different and independent cells. The images show time-lapse (0 and 30 min) Donor/FRET ratios (min 
and max) coded according to the indicated pseudocolor ramp. Calibration bar 20 μm. 
(B) Primary hippocampal neurons expressing an ER Calcium FRET probe (D1ER) were challenged 
with 100μM METH. FRET/ Donor emission ratios before (control; t=0 in the images) and after METH 
administration were normalized at 0 min. Symbols represent the mean + SEM of four different and 
independent cells. The images show time-lapse (0, 18 and 30 min) FRET/Donor ratios (min and max) 
coded according to the indicated pseudocolor ramp. Calibration bar 20 μm. 
 
 
 
 
 
 
 
Arthur et al (2000) have suggested that Src activation leads to a decreased RhoA 
activation through p190RhoGAP activation. RhoA is a low-molecular-weight guanine 
nucleotide binding proteins that gets active by switching from an inactive GDP-bound state to 
an active GTP-bound state (Govek et al, 2005). RhoA is responsible for regulating stress 
fiber formation and cell contraction as well as for modulating neuronal morphology (reviewed 
in Gonzalez-Billault et al, 2012; Nobes and Hall, 1995; Ridley and Hall, 1992). RhoA is also 
involved in numerous cell functions like migration, adhesion, survival, cell division, gene 
expression and vesicle trafficking (Jaffe and Hall, 2005). The link between c-Src activation 
and RhoA modulation is of primary interest for us since we have also observed that METH 
leads to down activation of RhoA in our primary hippocampal culture. As shown in figure 13, 
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Figure 13. FRET analysis for RhoA activity. Primary hippocampal neurons expressing a RhoA 
FRET probe (Raichu-RhoA) were challenged with 100μM METH. Donor/FRET emission ratios before 
(control; t=0 in the images) and after METH administration were normalized at 0 min. Symbols 
represent the mean + SEM of 23 processes in five different and independent cells. The images show 
time-lapse (0, 10 and 20 min) Donor/FRET ratios (min and max) coded according to the indicated 
pseudocolor ramp. Calibration bar 5 μm.    
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we used a FRET probe to assess RhoA activation state and observed a decrease in RhoA 
activation after 100 µM METH administration to the neurons. Although this link needs to be 
further explored, we can predict that the increased c-Src activation may lead to decreased 
RhoA activity, probably through p190RhoGAP. This decrease in RhoA activation may 
regulate METH-induced changes in neuronal morphology, which was observed by others 
and in previous experiments in our laboratory (Jedynak et al, 2007; Kiyatkin and Sharma, 
2009; Marshall et al, 2007).  
 
 
 
 
 
 
 
 
 
RhoA, as mentioned above, is involved in modulating neuronal morphology. In order 
to assess the possible influence of RhoA in neuronal morphology when exposure to METH 
occurs, we evaluated neuronal length and branching in neurons transfected with Venus or a 
constitutively active form of RhoA. The obtained results show that methamphetamine 
induces a significant increase in neuronal length (figure 14A). However, when RhoA is 
constitutively expressed, we no longer see an effect of methamphetamine (figure 14B). 
Moreover, Sholl analysis demonstrates that METH exposure results in increased neuronal 
branching, especially closer to the cell body. RhoA expression leads to an overall decrease 
of branching and METH no longer appears to induce this sort of increase (figure 14C). These 
results appear to indicate that RhoA does have a role in neuronal morphology and that the 
decrease in RhoA activity in response to methamphetamine exposure is necessary for the 
morphological alterations prompted by METH. 
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Figure 14. Morphological alterations in response to METH. Primary hippocampal neurons 
tranfected with GFP or RhoA CA were evaluated for neurite length and branching. Methamphetamine 
increases neurite length and branching. RhoA CA impairs METH effects on neurite length, which no 
longer increases. Furthermore, there is a decrease in branching in both control and METH exposed 
neurons. Statistical analysis was performed using a paired t-test for neuronal length and a two-way 
ANOVA for neuronal branching. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.5. Knockdown of Olfm4 protein expression in hippocampal neuronal 
cultures  
To further the possible role of Olfm4 under METH exposure, we silenced this protein 
in our cultures and evaluated the effect of METH with or without Olfm4 in pathways of 
interest, which were identified in chapter 3.4. 
In a first approach, we infected neurons with lentivirus expressing Olfm4 shRNA or 
DsRed to assess the protein expression levels of Olfm4. DsRed infected neurons allows us 
to control for the effects of infection and METH exposure without knocking down Olfm4. 
Although, we were not yet able to confirm the silencing of Olfm4 protein levels by western 
blot and therefore to confirm if the shRNA was in fact downregulating Olfm4 protein levels 
(the antibody initially used is no longer targeting our protein of interest even in positive 
A 
B 
C 
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Figure 15. pSrc expression expression in neurons infected with either DsRed or shRNA.Olfm4.  
METH does not appear to significantly affect the Src phosphorylation in DsRed infected primary 
hippocampal cultures when compared to control conditions. When knocking down Olfm4, Src 
phosphorylation decreases in both control and METH exposed neurons. Src acrivaiton in 
hippocampal neuronal cultures in control vs METH 100µM. Src was used as a loading control. 
Columns represent one independent experiment. 
controls, another batch will be ordered), we decided to proceed with our study (pending, of 
course, future confirmation). 
Src activation was then reanalysed by western blot to evaluate Src phosphorylation 
levels in hippocampal neurons infected with lentivirus expressing DsRed or Olfm4 shRNA 
and exposed or not to METH. Figure 15 represents these preliminary results (n=1), showing 
a promising decrease in Src phosphorylation levels (as a ratio to the total Src expression) in 
response to Olfm4 knockdown. Importantly, this may indicate that Olfm4 expression is 
required for Src activation. Also in this case, at 24h of exposure METH does not seem to 
affect Src phosphorylation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
As mentioned above, Src is involved in modulating MMPs (and in particularly MMP2), 
which were already reported to be affected by METH (Fernandes et al, 2016; Martins et al, 
2011). Therefore, we also became interested in evaluating how silencing Olfm4 could affect 
METH action over MMP increased release. In order to study the activity of MMPs activity, we 
collected the cultured condicioned medium of hippocampal neurons infected with lentivirus 
pSrc 60kDa 
Src 
60kDa 
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Figure 16. MMP2 activity evaluated in medium collected from neuronal cultures. Conditioned 
medium of infected 15 DIV hippocampal cultures was collected and processed for a zymography 
assay. Olfm4 knockdown appears to increase MMP2 activity, when exposed to METH. The results 
are the average of ±SEM of 4 independent experiments performed in different preparations. 
Statistical analysis was performed using a one-way ANOVA with Bonferroni post-hoc.  
 
expressing Olfm4 shRNA or DsRed, exposed or not to 100 µM METH for 24 hours, and 
analysed it through a gelatin zymography assay. Surprisingly, knocking down Olfm4 seems 
to induce an increase in MMP2 activity under METH exposure, although this difference is not 
statistically significant (figure 16). Although in endothelial cells we have reported a METH 
induced activation of MMP9 (Fernandes 2016), here, we were not able to detect MMP9 
activation signal. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To completely discard a role of Olfm4 in the expression and localization of ZO-1, we 
further assessed it in neurons infected with lentivirus expressing Olfm4 shRNA or DsRed, 
exposed or not to METH. As represented in figure 17, it seems that there are no differences 
between the different conditions. Furthermore, we also analysed ZO-1 expression by 
immunocytochemistry assays in neurons transfected with Olfm4 shRNA and treated or not 
with METH. These results are representative since we only analysed 1 independent 
experiment, and therefore require further experiments. 
 
 
MMP2 73kDa 
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Figure 17. ZO-1 expression in neurons infected with DsRed or shRNA.Olfm4.  
(A) METH does not appear to significantly alter ZO-1 expression in hippocampal cultured neurons 
infected with DsRed. Knocking down Olfm4 does not seem to affect ZO-1 expression in control vs 
METH exposed neurons. ZO-1 expression in hippocampal neuronal cultures in control vs METH 
100µM. GAPDH was used as a loading control. (B) ZO-1 expression in control Venus transfected 
neurons. (C) ZO-1 expression in METH 100µM Venus transfected neurons. 
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Chapter 4: Discussion and Conclusion 
Neuroinflammation is now seen as a serious consequence of drug abuse. Our aim 
was to study how methamphetamine might alter the expression of proteins that somehow 
contribute for neuroinflammation. We showed that Olfm4, a protein that has been linked to 
inflammatory processes, has its mRNA levels increased in response to METH exposure. 
Protein levels however, appear to be decreased. 
These contradictory results might be explained by cellular regulatory mechanisms, 
such as miRNA, which function as RNA silencing and in post-transcriptional regulation, 
potentially leading to mRNA degradation and, therefore, decreasing protein expression. Post-
transcriptional mechanisms responsible for mRNA translation into protein are not fully 
understood and may be accountable for this discrepancy. However, as mentioned earlier, 
Olfm4 is an extracellular cellular matrix protein which means that it is secreted by cells. One 
possible explanation for the decreased protein levels might be a METH-induced increase in 
protein secretion to the extracellular medium, resulting in virtual lower protein levels in the 
cell extract, and also to increased gene expression as a compensating mechanism. To clarify 
this issue, we tried to precipitate the protein present in culture medium using the TCA 
(trichloroacetic acid) method. This protocol uses TCA to precipitate proteins, which after 
precipitation are resuspended in protein extraction buffer for further analysis by western blot. 
However, we were not successful in this experiment since we were not able to properly 
resuspend proteins, and a further approach will include the analysis of the protein secreted 
using protein lyophilization.  
We first evaluated the effect of METH in the mRNA expression of inflammatory 
factors in neurons (IL-1β, TNF, iNOS, IL-6 and TGF-β), by qPCR. However, we were not able 
to detect mRNA levels of any of these factors, due to very low expression levels, making it 
undetectable by qPCR. This may indicate that neurons do not respond directly to METH by 
producing cytokines. In on-going work at our laboratory we have also seen that the 
conditioned medium of hippocampal neurons exposed to METH is not able to activate 
cultured primary microglia cells, indicating that neurons might not produce inflammatory 
factors in direct response to METH. 
Upon this challenge, we decided to shift our focus to extracellular matrix remodeling. 
Olfm4 has been described as being relevant for tumor growth and matrix shaping (Tomarev 
and Nakaya, 2009; Zhang et al, 2004) and previous reports from both our and other research 
groups have shown that METH affects several elements related to these functions 
(Fernandes et al, 2016; reviewed in Mulholland et al, 2016). As such, we decided to target 
several of those elements.  
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Integrins are extensively studied cell adhesion molecules that bind to the extracellular 
matrix and are involved known to be involved in synaptic plasticity. Previous works have 
shown that integrins may contribute to psychostimulant-reinstated drug-seeking, by 
modulating glutamatergic signaling (Wiggins et al, 2011). Laminin was also seen to be 
decreased after in vivo METH administration and was associated to BBB loss of integrity 
(Urrutia et al, 2012). Therefore β1 Integrin and Laminin become targets of interest in our 
study. Unfortunately, the expression of those proteins could not be determined with the 
antibodies used, and as we were not able to quantify it in control cells; these experiments will 
need to be repeated to clarify if this is simply due to low expressions levels in our cultures, or 
if we may need different antibodies. Our results show that methamphetamine does not alter 
Cldn5 or ZO-1 protein expression in cultured hippocampal neurons. These proteins are 
classically associated to endothelial cells and BBB function; however they are also 
expressed in different types of neurons and were reported to be altered in these cells in 
patients suffering from dementia (Romanitan et al, 2010). Furthermore, our laboratory has 
recently shown that CLdn5 displays both an altered expression and a significant 
translocation to cytosol in endothelial cells exposed to METH (Fernandes et al 2016), 
meaning that although here we do not see an effect at the expression level under METH 
exposure, we could still find evidence of translocation. For that reason we later tried to 
evaluate that for ZO-1 through immunocytochemistry, nevertheless we found also no 
differences in ZO-1 location.  
It has been described that MMP2 protein activity increases in response to METH 
(Fernandes et al 2016; Martins et al, 2011; Mizoguchi et al, 2008). We have assessed the 
activity of MMPs and it has also been described that MMP9 activity is influenced by Olfm4, 
since overexpressing this protein results in decreased expression of MMP9. (Park et al, 
2012). We have assessed the activity of MMPs in our hippocampal cultures. Interestingly, 
MMP2 activity in our neuronal cells was not affected by METH, as shown by zymography 
assay of the culture medium of hippocampal neuronal cultures. However, knocking-down 
Olfm4 seems to increase MMP2 activity, indicating that Olfm4 expression may have a role on 
regulating MMP2 activity under METH.  
Src family proteins have long been linked to several cellular functions and, among 
them, neuronal plasticity and extracellular matrix modeling (reviewed in Ohnishi et al, 2011). 
Of note, our laboratory has recently shown that methylphenidate (MPH), an amphetamine-
like stimulant commonly prescribed for attention deficit hyperactivity disorder, induces 
Rac1/NOX-dependent ROS generation and subsequent c-Src activation (Coelho-Santos et 
al, 2016). As such, we hypothesized that Src activity could be altered in hippocampal 
neurons in response to METH exposure. We tested this hypothesis through western blot, 
quantifying expression of Src and p-Src, which translates into active Src, and through FRET 
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assay, measuring c-Src activation in response to METH exposure. Our results indicate that 
methamphetamine increases c-Src activation in a prolonged way. These results might have a 
broader implication in neuronal response to methamphetamine considering Src pivotal role in 
modeling the activity of numerous proteins and, therefore, numerous cellular mechanisms. 
One specific protein that might be regulated by Src activation is RhoA. This protein 
activation, as mentioned before, has been linked to a decreased neuronal plasticity. 
Psychostimulants, like methamphetamine, are known to cause neurite outgrowth and 
increase the neuronal branching and density of dendritic spines (reviewed in Golden and 
Russo, 2012). Src activation has been suggested to precede RhoA inactivation, through 
p190RhoGAP activation (Arthur et al, 2000). In a parallel ongoing work in our laboratory, we 
have already seen that METH needs to down regulate the activity of RhoA to be able to 
induce increased morphologic complexity (unpublished data). Although this hypothesis 
needs to be further explored, we might have unveiled a possible pathway linking Src 
activation, RhoA diminished activity and higher neurite outgrowth. Schoenwaelder and 
Burridge (1999) suggested that integrins can transmit signals that lead to rearrangements in 
the actin cytoskeleton. Arthur et al (2000) suggested that Src activation, and consequent 
RhoA inactivation, is mediated by extracellular matrix proteins binding to integrins that will 
outset a signaling cascade that leads to Src activation and RhoA inactivation. Furthermore, 
our results may also indicate that Olfm4 is involved in Src activation, since reducing Olfm4 
expression decreased Src activation, even under METH-exposure. This experiment was 
performed in only one independent neuronal culture, and therefore requires repetition. Olfm4 
has been described to interact with integrins, and is likely that increased Olfm4 secretion 
could lead to an increased integrin binding, resulting in increased Src activation. Src would 
then activate p190RhoGAP which, by its turn, would decrease RhoA activity.   
To test this theory, our future work will begin by validating Olfm4 knockdown by 
qPCR, to make sure that we are fact reducing Olfm4 expression in hippocampal neurons. 
The next step will be to determine if Olfm4 knockdown has an effect in Src and RhoA 
activation. To do so, we can resort to western blot analyzes or to FRET assays. If our 
hypothesis is correct, when Olfm4 expression is reduced, we expect to observe a decrease 
in Src activation under METH exposure, while RhoA activation increases.  
Another approach will be to reduce Src expression or inhibit Src activity, and evaluate 
RhoA activation. This will allow us to stablish a direct link between Src and RhoA activation. 
To determine if the hypothetical pathway does involve p190RhoGAP activation, we could use 
the same strategy to assess this protein effect in the signaling pathway. 
In summary, we may have uncovered a new pathway that may contribute to the 
METH-induced neuronal morphological alteration. This pathway involves Src activation, and 
subsequent RhoA inhibition, which we have previously associated with increased neurite 
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outgrowth and branching (reviewed in Gonzalez-Billault et al, 2012). This pathway may be 
linked to our protein of interest Olfm4, since this protein has been shown to regulate 
integrins, which regulate Src activation, and Olfm4 shRNA decreased Src activation. Our 
future perspectives are to unravel the role of Olfm4 in this pathway, and dissect the effects in 
neuronal processes induced by METH, providing a new glimpse into the mechanisms by 
which METH alters neuronal and brain functioning. Importantly, the effects of Olmf4 in 
neuronal morphology and regulation of this signaling pathway may be relevant to understand 
METH addiction.  
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